FK 317

Drug Profile

FK 317

Latest Information Update: 26 Mar 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fujisawa
  • Class Cytostatic antibiotics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 26 Mar 2002 Discontinued - Phase-I for Solid tumours in USA (unspecified route)
  • 26 Mar 2002 Discontinued - Phase-II for Solid tumours in Japan (unspecified route)
  • 29 Aug 2001 A phase I study has been added to the Cancer adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top